Year All202620252024202320222021 June 23, 2025 ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study June 20, 2025 ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC May 12, 2025 ArriVent BioPharma Reports First Quarter 2025 Financial Results April 28, 2025 ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors March 3, 2025 ArriVent BioPharma Reports Full Year 2024 Financial Results January 21, 2025 ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers November 14, 2024 ArriVent BioPharma Reports Third Quarter 2024 Financial Results September 9, 2024 ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer August 14, 2024 ArriVent BioPharma Reports Second Quarter 2024 Financial Results August 12, 2024 ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer
June 23, 2025 ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study
June 20, 2025 ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC
January 21, 2025 ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers
September 9, 2024 ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer
August 12, 2024 ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer
